First Time Loading...

Carna Biosciences Inc
TSE:4572

Watchlist Manager
Carna Biosciences Inc Logo
Carna Biosciences Inc
TSE:4572
Watchlist
Price: 436 JPY -1.13%
Updated: May 9, 2024

Gross Margin
Carna Biosciences Inc

89.2%
Current
87%
Average
43.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
89.2%
=
Gross Profit
1.5B
/
Revenue
1.6B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
JP
Carna Biosciences Inc
TSE:4572
7.6B JPY
89%
US
Thermo Fisher Scientific Inc
NYSE:TMO
221.8B USD
40%
US
Danaher Corp
NYSE:DHR
184.8B USD
58%
US
Agilent Technologies Inc
NYSE:A
41.8B USD
51%
CH
Lonza Group AG
SIX:LONN
38B CHF
36%
US
IQVIA Holdings Inc
NYSE:IQV
41.4B USD
35%
KR
Samsung Biologics Co Ltd
KRX:207940
55.6T KRW
49%
US
Mettler-Toledo International Inc
NYSE:MTD
27B USD
59%
US
West Pharmaceutical Services Inc
NYSE:WST
26.8B USD
37%
IE
ICON PLC
NASDAQ:ICLR
25.8B USD
30%
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.8B EUR
43%
Carna Biosciences Inc
TSE:4572
Country JP
Market Cap 7.6B JPY
Gross Margin
89%
Thermo Fisher Scientific Inc
NYSE:TMO
Country US
Market Cap 221.8B USD
Gross Margin
40%
Danaher Corp
NYSE:DHR
Country US
Market Cap 184.8B USD
Gross Margin
58%
Agilent Technologies Inc
NYSE:A
Country US
Market Cap 41.8B USD
Gross Margin
51%
Lonza Group AG
SIX:LONN
Country CH
Market Cap 38B CHF
Gross Margin
36%
IQVIA Holdings Inc
NYSE:IQV
Country US
Market Cap 41.4B USD
Gross Margin
35%
Samsung Biologics Co Ltd
KRX:207940
Country KR
Market Cap 55.6T KRW
Gross Margin
49%
Mettler-Toledo International Inc
NYSE:MTD
Country US
Market Cap 27B USD
Gross Margin
59%
West Pharmaceutical Services Inc
NYSE:WST
Country US
Market Cap 26.8B USD
Gross Margin
37%
ICON PLC
NASDAQ:ICLR
Country IE
Market Cap 25.8B USD
Gross Margin
30%
Sartorius Stedim Biotech SA
PAR:DIM
Country FR
Market Cap 18.8B EUR
Gross Margin
43%

Profitability Report

View the profitability report to see the full profitability analysis for Carna Biosciences Inc.

Full Profitability Report

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
89.2%
=
Gross Profit
1.5B
/
Revenue
1.6B
What is the Gross Margin of Carna Biosciences Inc?

Based on Carna Biosciences Inc's most recent financial statements, the company has Gross Margin of 89.2%.

ALPHA SPREAD
Join more than 135,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.